Patrick Dempsey Teams up With Breakaway from Cancer(R)

AmgenPatrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer(R) initiative.

"Cancer entered my life in 1997 when my mother was first diagnosed with ovarian cancer," explained Dempsey. "I remember the feelings well - it was overwhelming. My family was trying to come to terms with the fear and shock of the diagnosis, while also working to sort through vast amounts of information to try and make the 'right' decisions for my mother's care."

Dempsey first teamed up with Breakaway from Cancer in 2007 to help bring the issue of better supporting patients to the forefront. In 2008, he founded The Patrick Dempsey Center for Cancer Hope & Healing at the Central Maine Medical Center -- the same hospital where Patrick was born and his mother received her cancer treatment.

Patrick Dempsey has now filmed a public service announcement (PSA) to raise awareness of the wide range of resources available to help people fight cancer. In the video, Dempsey talks about the challenges of choosing the right path and making the right choices - and urges people to take advantage of the free resources available via Breakaway from Cancer.

Breakaway from Cancer represents a collaboration between Amgen and four nonprofit partner organizations to connect individuals with support services ranging from cancer prevention, assistance during treatment, and embracing survivorship. The Breakaway from Cancer website provides a 'one-stop shop' of essential resources, including a navigator tool to help maneuver through the complicated maze of online information that currently exists. The tool conducts a targeted search based on user-entered criteria from more than 100 hand-selected credible cancer websites to offer patients the information they need.

Wherever you may be in your cancer journey, Breakaway from Cancer is here to help you find your way," Dempsey explains. "Whether you're newly diagnosed or have finished your treatment, breakawayfromcancer.com has resources you can use - all in one place."

To watch the PSA, visit http://www.breakawayfromcancer.com.

About Breakaway from Cancer(R)
Founded in 2005 by Amgen, Breakaway from Cancer(R) is a national initiative to increase awareness of important resources available to people affected by cancer - from prevention through survivorship. Through Breakaway from Cancer, Amgen has joined forces with four nonprofit partner organizations: Prevent Cancer Foundation, Cancer Support Community (formerly known as The Wellness Community), Patient Advocate Foundation, and National Coalition for Cancer Survivorship. These organizations offer a broad range of support services complementing those provided by a patient's team of healthcare professionals.

About Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...